Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers

Abstract

French

Background:

A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration.

Objective:

To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate.

Methods:

The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009–2011) and the Annual Meeting of the American Academy of Dermatology (2009–2012) were also searched.

Results:

Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate.

Conclusion:

Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.

Get full access to this article

View all access options for this article.

References

Criscione

Weinstock

Naylor

. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523–30, doi:10.1002/cncr.24284.

Canadian Cancer Society, Statistics Canada. Canadian cancer statistics 2011. Available at: http://www.cancer.ca/∼/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/PDF%20-%20Policy%20-%20Canadian%20Cancer%20Statistics%20-%20English/Canadian%20Cancer%20Statistics%202011%20-%20English.ashx (accessed April 20, 2012).

Vatve

Ortonne

Birch-Machin

. Management of field change in actinic keratosis. Br J Dermatol 2007;157 Suppl 2:21–4, doi:10.1111/j.1365-2133.2007.08268.x.

US Food and Drug Administration. Drugs at FDA, Aldara product monograph. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf (accessed April 26, 2012).

Sanofi-aventis, Carac product monograph. Available at: http://products.sanofi.us/carac/carac.html (accessed April 26, 2012).

Valeant Pharmaceuticals. Efudex product monograph. Available at: http://www.valeant.com/fileRepository/products/PI/Efudex-40_Cream_5_Solution_2-5_PI_Apr04.pdf (accessed April 26, 2012).

PharmaDerm. Solaraze product monograph. Available at: https://www.solaraze.com/solaraze/pdf/solaraze_pi.pdf (accessed April 26, 2012).

Medicis. Zyclara product monograph. Available at: http://pi.me-dicis.us/zyclara.pdf (accessed April 25, 2012).

US Food and Drug Administration. Drugs at FDA, Picato. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (accessed March 27, 2012).

10.

Kedei

Lundberg

Toth

. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004;64:3243–55, doi:10.1158/0008-5472.CAN-03-3403.

11.

Ogbourne

Hampson

Lord

. Proceedings of the First International Conference on PEP005. Anticancer Drugs 2007;18:357–62, doi:10.1097/CAD.0b013e3280149ec5.

12.

Bosco

Melloni

Celeghini

. Fine tuning of protein kinase C (PKC) isoforms in cancer: Shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011;11:185–99, doi:10.2174/138955711795049899.

13.

Ogbourne

Suhrbier

Jones

. Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833–9, doi:10.1158/0008-5472.CAN-03-2837.

14.

Challacombe

Suhrbier

Parsons

. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123–32.

15.

Cozzi

Parsons

Ogbourne

. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 2006;66:10083–91, doi:10.1158/0008-5472.CAN-06-0348.

16.

Shukla

Lee

. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 2010;70:4509–19, doi:10.1158/0008-5472.CAN-09-4303.

17.

Hampson

Chahal

Khanim

. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005;106:1362–8, doi:10.1182/blood-2004-10-4117.

18.

Olsnes

Ersvaer

Ryningen

. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009;145:761–74, doi:10.1111/j.1365-2141.2009.07691.x.

19.

Hampson

Wang

Milverton

. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis 2010;15:946–55, doi:10.1007/s10495-010-0507-7.

20.

Lee

Hampson

Coulthard

. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. J Biol Chem 2010;285:23889–98, doi:10.1074/jbc.M109.041962.

21.

Benhadji

Serova

Ghoul

. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer 2008;99:1808–15, doi:10.1038/sj.bjc.6604642.

22.

Serova

Ghoul

Benhadji

. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther 2008;7:915–22, doi:10.1158/1535-7163.MCT-07-2060.

23.

Ghoul

Serova

Astorgues-Xerri

. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res 2009;69:4260–9, doi:10.1158/0008-5472.CAN-08-2837.

24.

Gardner

Hoang-Le

. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine 2009;27:3053–62, doi:10.1016/j.vac-cine.2009.03.025.

25.

Ersvaer

Kittang

Hampson

. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: A balance between efficacy and toxicity. Toxins (Basel) 2010;2:174–94.

26.

Rosen

Gupta

Tyring

. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012;66:486–93, doi:10.1016/j.jaad.2010.12.038.

27.

Gillespie

Zhang

Hersey

. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther 2004;3:1651–8.

28.

Hampson

Kavanagh

Smith

. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother 2008;57:1241–51, doi:10.1007/s00262-008-0458-9.

29.

Cozzi

Ogbourne

James

. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012;132:1263–71, doi:10.1038/jid.2011.418.

30.

Siller

Gebauer

Welburn

. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study Australas J Dermatol 2009;50:16–22, doi:10.1111/j.1440-0960.2008.00497.x.

31.

Spencer

. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01% and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol 2010;62 Suppl 3:AB105.

32.

Anderson

Schmieder

Werschler

. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009;60:934–43, doi:10.1016/j.jaad.2009.01.008.

33.

Rosen

. Ingenol mebutate (PEP005) gel for actinic keratosis: Safety, efficacy, and development status. Australas J Dermatol 2009;50 Suppl 1:A5.

34.

Lam

TSK

Wong

Leung

Fung

. A case report of ocular injury by Euphorbia plant sap. Hong Kong J Emerg Med 2009;16:267–70.

35.

Eke

Al-Husainy

Raynor

. The spectrum of ocular inflammation caused by Euphorbia plant sap. Arch Ophthalmol 2000;118:13–6, doi:10.1001/archopht.118.1.13.

36.

Schmieder

. Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100cm² in patients with actinic keratoses. J Am Acad Dermatol 2010;62 Suppl 3:AB106.

37.

Lebwohl

Swanson

Anderson

. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366:1010–9, doi:10.1056/NEJMoa1111170.

38.

Jorizzo

Stewart

Bucko

. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-,2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002;70:335–9.

39.

Weiss

Menter

Hevia

. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70(2 Suppl):22–9.

40.

Lebwohl

Dinehart

Whiting

. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714–21, doi:10.1016/j.jaad.2003.12.010.

41.

Szeimies

Gerritsen

Gupta

. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547–55, doi:10.1016/j.jaad.2004.02.022.

42.

Korman

Moy

Ling

. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467–73, doi:10.1001/archderm.141.4.467.

43.

Hanke

Beer

Stockfleth

. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62:573–81, doi:10.1016/j.jaad.2009.06.020.

44.

Jorizzo

Markowitz

Lebwohl

. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010;9:1101–8.

45.

Swanson

Abramovits

Berman

. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62:582–90, doi:10.1016/j.jaad.2009.07.004.

46.

Gebauer

Shumack

Cowen

. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: A phase II, randomized placebo-controlled trial. Br J Dermatol 2009;161:897–903, doi:10.1111/j.1365-2133.2009.09260.x.

47.

Rivers

Arlette

Shear

. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146:94–100, doi:10.1046/j.1365-2133.2002.04561.x.

48.

Wolf

Jr Taylor

Tschen

. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709–13, doi:10.1046/j.1365-4362.2001.01324.x.

49.

US Food and Drug Administration. Drugs at FDA, Solaraze, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf (accessed May 11, 2012).

50.

Stockfleth

Meyer

Benninghoff

. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498–502, doi:10.1001/archderm.138.11.1498.

51.

Ooi

Barnetson

Zhuang

. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol 2006;154:72–8, doi:10.1111/j.1365-2133.2005.06932.x.

52.

Gold

Melgaard

Larsson

. Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. J Am Acad Dermatol 2012;66 (4 Suppl 1):AB154.

53.

Hanke

Swanson

Bruce

. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol 2011;10:165–70.

54.

Stough

Bucko

Vamvakias

. Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: An 18-month open-label study. Cutis 2010;85:267–73.

55.

Lawrence

Cox

Cockerell

. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995;131:176–81, doi:10.1001/archderm.1995.01690140060009.

56.

Witheiler

Lawrence

Cox

. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997;23:191–6, doi:10.1016/S1076-0512(97)00008-3.

57.

Krawtchenko

Roewert-Huber

Ulrich

. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157 Suppl 2:34–40, doi:10.1111/j.1365-2133.2007.08271.x.

58.

Lee

Harwell

Loven

. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg 2005;31:659–64, doi:10.1111/j.1524-4725.2005.31608.

59.

Jorizzo

Dinehart

Matheson

. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265–8, doi:10.1016/j.jaad.2007.01.047.

60.

Nelson

Rigel

. Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: One-year evaluation. J Clin Aesthet Dermatol 2009;2:20–5.

61.

Kane-Maguire

Moseley

Cozzi

S-J

. Modulation of fibroblast phenotype and extracellular matrix composition by ingenol mebutate may be associated with scar resolution and improved dermal cosmesis. J Am Acad Dermatol 2012;66 (4 Suppl 1):AB218.

62.

Ramsay

Suhrbier

Aylward

. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 2011;164:633–6.

63.

Nouri

Choudhary

McLeod

. Treatment of basal cell carcinoma. In: Maibach

Gorouhi

, editors. Evidence based dermatology. 2nd ed. Shelton (CT): People's Medical Publishing House-USA; 2011. p. 649–71.

64.

Siller

Rosen

Freeman

. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: Results of a randomized phase IIa trial. Australas J Dermatol 2010;51:99–105, doi:10.1111/j.1440-0960.2010.00626.x.

65.

LEO Pharma. Pipeline. Available at: http://www.leo-pharma.com/Home/Research-and-Development/Pipeline.aspx (accessed April 25, 2012).